Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "heart-failure"

98 News Found

Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets
News | August 31, 2022

Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets

Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA


Alembic Pharmaceuticals receives USFDA final approval for Chlorthalidone Tablets USP
Drug Approval | August 29, 2022

Alembic Pharmaceuticals receives USFDA final approval for Chlorthalidone Tablets USP

he approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Hygroton Tablets, 25 mg and 50 mg, of Sanofi Aventis US. LLC (Sanofi).


JB Pharma ranks 23 in Indian pharma market
News | August 26, 2022

JB Pharma ranks 23 in Indian pharma market

JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.


AI to shape future outcomes in cardiovascular care, says GlobalData
Digitisation | August 11, 2022

AI to shape future outcomes in cardiovascular care, says GlobalData

AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.


India’s first 4th Gen transcatheter mitral valve performed at Apollo Chennai
News | July 21, 2022

India’s first 4th Gen transcatheter mitral valve performed at Apollo Chennai

Dr Sai Satish, Sr. Consultant Interventional Cardiologist performs India’s first 3 successful G4-Transcatheter Edge to Edge (G4–TEER) mitral valve repairs


COVID-19 infected 9-year-child successfully gets a heart transplant at Masinda Heart Institute
Healthcare | June 16, 2022

COVID-19 infected 9-year-child successfully gets a heart transplant at Masinda Heart Institute

Many kids who have heart transplants live a normal, healthy life once they recover from surgery.


Dapagliflozin met primary endpoint in DELIVER Phase III trial
Biotech | May 23, 2022

Dapagliflozin met primary endpoint in DELIVER Phase III trial

Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction


BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
Biotech | May 17, 2022

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca

A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI


Erectile dysfunction drugs help prevent death and complications due to heart disease
Healthcare | May 15, 2022

Erectile dysfunction drugs help prevent death and complications due to heart disease

Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality


Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Biotech | April 29, 2022

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo